Overview
BioXcel Therapeutics is developing BXCL501, a sublingual film formulation of dexmedetomidine for acute agitation in bipolar disorder and schizophrenia, leveraging AI-driven drug repurposing.
More in Neuropharmaceuticals
Latest industry news
China Performs World's First Commercial BCI Implant, Marking a Pivotal Moment in the Global Brain-Computer Interface Race
2026-07-16 · Industry
NIH Confirms Brain-Computer Device Restores Speech in Human Patient
2026-07-15 · Research
Neurovalens Wins FDA Approval for Wearable PTSD Therapy Aimed at US Veterans
2026-07-14 · Policy
BRYM Raises €650K to Build Wearable Neurofeedback Platform for Consumer and Clinical Markets
2026-07-13 · Funding
Company details
Category
💊 Neuropharmaceuticals
Location
New Haven, CT, USA
Funding
Public
Website
www.bioxceltherapeutics.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →